drugset / Trial / NCT03297463
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1b/2 study designed to evaluate combination of the human T-cell cytokine Interleukin-2 (IL-2) and a checkpoint inhibitor Ipilimumab immediately following a course of hypofractionated palliative radiation therapy in the management of unresectable, relapsed/refractory metastatic melanoma.
Timeline
- Start
- 2018-01-31
- Primary completion
- 2020-02-01
- Completion
- 2020-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 0.1 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 1.5 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | aldesleukin | Protein / enzyme biologic | — | — |